TEM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tempus AI is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants to act now. The fundamentals and news are improving, but the stock is still technically mixed, analyst targets have been cut overall, and the options/price action do not show a clean high-conviction entry. If forced to act today, I would not buy aggressively here; I would hold and wait for a better setup.
TEM is showing a mixed-to-bullish short-term momentum profile but a bearish broader trend. MACD histogram is positive and expanding, which supports near-term upside momentum. However, the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5, indicating the longer trend is still weak. RSI_6 at 77.251 suggests the stock is short-term stretched rather than offering a fresh value entry. Price is currently 50.77, just above pivot 46.964 and near R1 50.566, so it is testing resistance rather than breaking out cleanly. Pre-market is up 4.21%, but regular session was down 0.66%, showing intraday uncertainty. Overall technical setup is not ideal for an impatient beginner investor seeking a long-term entry.
Tempus also has 37 research abstracts accepted for ASCO 2026, reinforcing momentum in precision medicine and oncology research. Hedge funds are reportedly buying aggressively, with buying up 884.13% last quarter, which is a strong institutional positive. Cathie Wood also viewed the recent 20% decline as a buying opportunity, adding supportive sentiment.
H.C. Wainwright cut its target to $64 from $95, BTIG to $80 from $90, and Baird to $59 from $68, reflecting valuation pressure and concerns about widening operating losses. Jefferies initiated Underperform with a $35 target, citing reimbursement risk and an unclear catalyst path in diagnostics. Technically, the stock remains below a healthy long-term trend structure, and the current price is pressing resistance rather than showing a low-risk entry. The stock trend estimate also points to weakness over the next week and month.
Latest quarter information is limited in the provided data, but analyst commentary around Q1 says Tempus AI posted a mixed report. Revenue growth was encouraged and 2026 revenue guidance was slightly raised, yet operating loss widened compared with past quarters. TD Cowen said strong growth was largely in line with expectations, while other firms pointed to valuation pressure after results. Because the latest quarter season is Q1 2026, the picture is one of strong top-line expansion but continued loss-making execution.
Wall Street is overall constructive but less enthusiastic than before. Most firms still carry Buy/Outperform/Overweight views, but price targets have generally been reduced after Q1, showing a more cautious stance on valuation and profitability. Positives: growth, strategic partnerships, AI-driven diagnostics, genomics momentum, and new FDA approval. Cons: widening operating losses, reimbursement uncertainty, and lack of a clearly visible step-function catalyst in the near term. Net view: pros still outweigh cons for long-term believers, but the lowered targets show diminishing near-term upside confidence.
